Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway

The prevalence of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) is increasing world-wide in parallel to the increase of the obesity epidemic. Insulin resistance (IR) and the accumulation of triglyceride-derived toxic lipid metabolites play a key role in its patho...

Descripción completa

Detalles Bibliográficos
Autores principales: Filozof, Claudia, Goldstein, Barry J., Williams, Richard N., Sanyal, Arun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2015
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532706/
https://www.ncbi.nlm.nih.gov/pubmed/26201461
http://dx.doi.org/10.1007/s40265-015-0437-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4532706/
https://www.ncbi.nlm.nih.gov/pubmed/26201461
http://dx.doi.org/10.1007/s40265-015-0437-3

Ejemplares similares